# US 2026/0000712 A1 · Method for modulating glucagon-like peptide 1 (glp-1) agonist induced muscle loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0000712 A1
- Document ID: US20260000712A1
- Status: Published application
- Kind: A1
- Application number: 19/094,351
- Filed: 2025-03-28
- Published: 2026-01-01
- Earliest claimed: 2024-03-28
- Assignees: Celularity Inc.
- Applicants: Celularity Inc.
- Inventors: Sharmila KOPPISETTI; Robert J. HARIRI; Joseph GLEASON; Rajarajeswari SIVALENKA; Lin KANG; Anna GOSIEWSKA
- Web page: https://patentgrep.com/patent/US20260000712A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein is a method of ameliorating muscle loss in a subject induced from the treatment of the subject with a GLP-1 agonist with the administration to the subject of a therapeutically effective amount of a placenta derived biological material having a continuous lipid bilayer membrane

## Claims

### Claim 1

A method for modulating Glucagon-Like Peptide 1 (GLP-1) agonist induced muscle loss in a subject being treated with a GLP-1 agonist, comprising administrating to the subject a therapeutically effective amount of a placenta derived biological material having a continuous lipid bilayer membrane, an umbilical cord derived biological material having a continuous lipid bilayer membrane, or a combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein modulating the GLP-1 agonist induced muscle loss in the subject comprises: (a) retarding the GLP-1 agonist induced muscle loss; (b) arresting the GLP-1 agonist induced muscle loss; or (c) ameliorating the GLP-1 agonist induced muscle loss.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biological material having a continuous lipid bilayer comprises; (a) a population of placenta derived adherent cells; (b) secretomes isolated from placenta; (ii) umbilical cord; or (iii) a combination of (i) and (ii); (b) exosomes secreted from cells of a population of placenta derived adherent cells; or (c) a combination of (a) and (b).

### Claim 4 (depends on 3)

The method of claim 3, wherein the secretomes isolated from placenta contain exosomes.

### Claim 5 (depends on 3)

The method of claim 3, wherein the secretion of the exosomes from the placenta derived adherent cells occurs (a) in vivo, (b) in vitro, (c) ex vivo, or (d) any combination of (a)-(c).

### Claim 6 (depends on 1)

The method of claim 1, wherein administration of the biological material having a continuous lipid bilayer to the subject is selected from the group consisting of intradermal administration, subcutaneous administration, intramuscular administration, and intravenous administration.

### Claim 7 (depends on 6)

The method of claim 6, wherein administration of the biological material having a continuous lipid bilayer is intramuscular administration.

### Claim 8 (depends on 1)

The method of claim 1, wherein the placenta derived adherent cells comprise: (a) PDA-001 cells; (b) PDA-002 cells; or (c) a combination of (a) and (b).

### Claim 9 (depends on 1)

The method of claim 1, wherein the GLP-1 agonist comprises: (a) dulaglutide; (b) exenatide; (c) exenatide extended-release; (d) liraglutide; (e) dulaglutide; (f) semaglutide injection; (g) semagulutide tablet; (h) lixisenatide; (i) albiglutide; (j) tirzepatide; or (k) efpeglenatide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject is being treated with a GLP-1 agonist for:
(a) the prevention, treatment or prevention and treatment of diabetes;
(b) the delaying or preventing of diabetic disease progression;
(c) the prevention, treatment or prevention and treatment of eating disorders; or
(d) any combination of (a)-(d).

### Claim 11

A method for modulating GLP-1 agonist induced muscle loss in a subject being treated with a GLP-1 agonist, comprising the administration to the subject of a therapeutically effective amount of:
(a) a population of placenta derived adherent cells;
(b) exosomes secreted from placenta derived adherent cells;
(c) secretomes isolated from placenta; or
(d) any combination of (a)-(c).

### Claim 12 (depends on 11)

The method of claim 11, wherein the secretomes isolated from placenta contain exosomes.

### Claim 13 (depends on 11)

The method of claim 11, wherein modulating the GLP-1 agonist induced muscle loss in the subject comprises: (a) retarding the GLP-1 induced muscle loss; (b) arresting the GLP-1 induced muscle loss; or (c) ameliorating the GLP-1 agonist induced muscle loss.

### Claim 14 (depends on 11)

The method of claim 11, wherein the subject is being treated with the GLP-1 agonist for: (a) type II diabetes; (b) weight loss; or (c) a combination of (a) and (b).

### Claim 15 (depends on 11)

The method of claim 11, wherein the administration is selected from the group consisting of intradermal administration, subcutaneous administration, intramuscular administration, and intravenous administration.

### Claim 16 (depends on 15)

The method of claim 15, wherein administration is intramuscular administration.

### Claim 17 (depends on 11)

The method of claim 11, wherein the placenta derived adherent cells comprise: (a) PDA-001 cells; (b) PDA-002 cells; or (c) a combination of (a) and (b).

### Claim 18 (depends on 11)

The method of claim 11, wherein the GLP-1 agonist comprises: (a) dulaglutide; (b) exenatide; (c) exenatide extended-release; (d) liraglutide; (e) dulaglutide; (f) semaglutide injection; (g) semagulutide tablet; (h) lixisenatide; (i) albiglutide; (j) tirzepatide; or (k) efpeglenatide.
